Biotech Takes Electrifying Approach To Developing An HIV Vaccine
In the tumultuous quest to create an effective HIV vaccine, an approach that combines a DNA vaccine with a jolt of electricity looks to be a promising candidate in monkeys, but more data is needed in humans before breaking out the champagne, researchers say
You may also be interested in...
Plans for PAVE 100, the National Institute on Allergy and Infectious Diseases' Phase IIb HIV vaccine study, remain on hold until the next wave of Merck's STEP data - also expected to aid preclinical vaccine development - is released, researchers say
In some instances, the vaccine may have led to an increase in HIV infections.
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.